36 results about "Indirect immunofluorescence" patented technology

The invention provides a full-automatic indirect immunofluorescence interpretation method and system, a storage medium and a program product, and relates to the technical field of indirect immunofluorescence detection.The method comprises the steps that when identification information of a target sample is obtained, a plurality of sealed antigen slides are placed in slide carrying groove positions of a bearing platform in batches, and the target sample is obtained; driving the bearing platform through the transmission mechanism to sequentially move the plurality of antigen slides to the imaging area, and performing positioning and fixing operation on the antigen slides entering the imaging area by using the positioning and clamping device; sequentially carrying out multi-view scanning on the antigen slides entering the imaging area to obtain multi-view fluorescence images, and splicing the fluorescence images to generate a fluorescence panoramic image; performing feature extraction on the panoramic image, determining a fluorescence karyotype category and a target fluorescence intensity value, and determining an antibody titer according to the category, the intensity value and dilution information; and performing association mapping on the titer, the category and the panoramic image according to the identification information to generate a fluorescence interpretation result.

The application belongs to the technical field of biology and particularly relates to an African swine fever virus pNP868R protein monoclonal antibody and a preparation method and application thereof. The application takes the pNP868R protein prepared by eukaryotic expression as an antigen, immunizes BALB / c mice, uses hybridoma technology, and obtains a hybridoma cell line capable of stably secreting the anti-African swine fever virus pNP868R protein monoclonal antibody through cell fusion, indirect ELISA method screening, limited dilution method subcloning and hybridoma continuous passage culture. The application also obtains an African swine fever virus pNP868R protein monoclonal antibody. The monoclonal antibody has high affinity with the pNP868R protein and can be applied in Western-Blot experiments, indirect immunofluorescence experiments, immunoprecipitation experiments and the capture of proteins interacting with pNP868R, and can be used for the diagnosis, prevention or treatment of African swine fever.

The invention belongs to the technical field of plant pharmacy, and particularly relates to an effect of pigeonpea in resisting respiratory syncytial virus infection. Detecting that the pigeon pea protein extract is non-toxic to HEp-2 cells through a cell proliferation detection kit; a cell activity detection method and an indirect immunofluorescence method are adopted to determine that the pigeon pea protein extract has an obvious inhibition effect on the respiratory syncytial virus, the activity of inhibiting the respiratory syncytial virus after the pigeon pea protein is subjected to enzymolysis by alkaline protease is improved, and pigeon peas have relatively high biological safety and relatively strong respiratory syncytial virus infection resistance.

The invention discloses application of ailanone in preparation of a medicine for treating feline infectious peritonitis, and belongs to the field of biological medicine. The change of the expression quantity of the feline infectious peritonitis virus N protein is detected through indirect immunofluorescence and western blot, and the change of the quantity titer of the feline infectious peritonitis virus is detected through TCID50. Results show that ailanone has an obvious effect of resisting the feline infectious peritonitis virus, the inhibitory effect on the feline infectious peritonitis virus is enhanced along with increase of the drug concentration, and the half effective concentration is 0.09 mu M. Meanwhile, drug inhibition tests show that ailanone has no inhibition effect on feline calicivirus. The invention provides a novel therapeutic drug and strategy for treating feline infectious peritonitis.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of an N protein polyclonal antibody of a horse coronavirus. The polyclonal antibody is prepared by truncation expression of the horse coronavirus N protein, and a material is provided for research on inhibition of host innate immune mechanism by the horse coronavirus N protein. Prokaryotic expression is carried out on the N protein of the equine coronavirus, the polyclonal antibody is prepared, and a method and a material are provided for molecular research and mechanism research of the equine coronavirus. According to the invention, in combination with bioinformatics analysis of an N protein of the horse coronavirus, a pGEX-6p-N3 recombinant plasmid is constructed, and prokaryotic expression is carried out, so that a purified recombinant protein is obtained. After a mouse is immunized by the recombinant protein, a polyclonal antibody is obtained, an indirect ELISA method detects that the polyclonal antibody has good titer, Western Blot detection has good reactivity, and the polyclonal antibody can be applied to an indirect immunofluorescence test.

The invention provides an application and a method of an RSAD2 agonist glycopyrronium in resisting RSV infection. The method comprises the following steps: S1, virtual screening and molecular docking; s1.1, performing virtual screening and molecular docking; s1.2, carrying out molecular dynamics simulation; s2, cell culture and RSV infection; s3, performing RT-qPCR detection on the expression of the RSAD2 and the virus load of the RSV; s4, performing Westernblot analysis on the influence of a small molecule compound on the expression of the RSAD2; s5, CCK8 is used for detecting the toxicity of the compound to Beaas-2b cells; s6, carrying out indirect immunofluorescence detection on a fluorescence signal of the RSV; s7, animal model establishment; s8, carrying out HE dyeing; s9, carrying out enzyme-linked immunosorbent assay (ELISA); and S10, statistical analysis. According to the present invention, the small molecule agonist targeting the host immune factor RSAD2 is screened, the endogenous antiviral factor is activated from the host perspective, the drug resistance problem caused by direct virus targeting is avoided, the RSAD2 is adopted as the host natural antiviral molecule, the activation strategy has good targeting property and good safety, and the efficient anti-RSV effect under the low toxic-side effect is achieved.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, YKKLHK(162860), was artificially synthesized in a solid phase. Using artificially expressed PEDV Nsp5 protein, the peptide was screened using an ELISA assay. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 162860 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 162860 sequence significantly inhibited PEDV infection.

The invention relates to the technical field of glass slides for biomedical detection, and particularly discloses a high-adhesion type glass slide for indirect immunofluorescence analysis experiments. The glass slide comprises a substrate, a transition layer and a functional layer, the transition layer is arranged on the surface of the substrate, is made of metal oxide and is used for improving the bonding stability of the substrate and the functional layer; the functional layer is arranged on the surface of the transition layer and is prepared by compounding modified polyacrylamide containing amino / carboxyl and nano-particles, and the sample adhesion is synergistically enhanced through specific combination of functional groups and a nanoscale surface rough structure. Performance tests show that the glass slide has an adhesion rate of more than or equal to 95% on cell and tissue slices, washing resistance of more than or equal to 5 times and a fluorescence signal variable coefficient of less than or equal to 5%, can effectively solve the problems that the existing glass slide sample is easy to fall off and poor in detection repeatability, remarkably improves the accuracy of indirect immunofluorescence analysis, and is suitable for scenes such as clinical diagnosis and pathological detection.

The application is used for analyzing the S1-CTD region of the PEDV S protein crystal structure by means of a machine learning model, and a polypeptide sequence FWKSKR (110766) with potential is screened from the target protein by polypeptide virtual screening technology. The 110766 sequence is artificially synthesized on a solid phase, and the polypeptide is screened by means of ELISA experiment using artificially expressed PEDV S1 protein. The affinity constant of the polypeptide and the target protein is identified by means of surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 110766 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by means of fluorescent quantitative PCR and indirect immunofluorescence experiment. The results show that the 110766 sequence can significantly inhibit the infection of PEDV.

The application discloses a kind of H9N2 subtype AIV multi-copy M2e protein monoclonal antibody, heavy chain and light chain variable region respectively have the amino acid sequence of sequence table SEQ.ID.NO.1 and SEQ.ID.NO.2.The related cell line and its preparation method are also established according to this.The preservation number of hybridoma cell strain 4E10-A10 of the application is CCTCC NO:C202328, and test shows that the anti-multi-copy M2e protein monoclonal antibody secreted by it has high specificity, sensitivity, can specifically recognize 2M2e, 3M2e and 4M2e recombinant protein and the cell expressing H9N2 subtype avian influenza virus 3M2e protein, and is suitable for indirect immunofluorescence detection and Western-blot identification.In conclusion, the application provides material and technical support for the mechanism research of AIV M2e monoclonal antibody to AIV and the application effect evaluation of broad-spectrum vaccine taking AIV M2e protein as target.

This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening, a peptide sequence of FWKEAK (110616) with potential affinity for the target protein was identified. The 110616 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 110616 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 110616 sequence significantly inhibited PEDV infection.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

The invention relates to a single-person indirect immunofluorescence detection method and a single-person indirect immunofluorescence detection system. A single-person reaction container is used as a fixing and detection platform for indirect immunofluorescence detection; an independent sample detection process is realized by adopting automatic liquid treatment and optical imaging; image features are automatically processed, and signals are quantized and output in a classified mode. Indirect immunofluorescence detection is directly optimized and designed from the aspect of a single-person reaction container, the problem of batch processing delay is solved, and indirect immunofluorescence detection is directly carried out on a single sample; the problem of limited degree of automation is solved, samples do not need to be transferred manually, optical imaging does not need to be set manually, and a full-automatic indirect immunofluorescence detection system is realized; the problems of sample confusion and low flexibility are solved, batch glass slides do not need to be repeatedly utilized, and emergency samples can be quickly inserted into a detection queue; the device solves the problem of low expandability, can be cascaded with a traditional analysis instrument, can be used in parallel connection with a plurality of single-thread detection devices, and is suitable for laboratories of various scales.

The invention relates to the technical field of antibodies, in particular to a 3D protein monoclonal antibody and application thereof. The monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises the following three complementary determining regions CDR: CDR1 shown as SEQ ID No.5, CDR2 shown as SEQ ID No.6, and CDR3 shown as SEQ ID No.7; the heavy chain variable region comprises the following three complementary determining regions: CDR1 shown as SEQ ID No.5, CDR2 shown as SEQ ID No.6, and CDR3 shown as SEQ ID No.7; the light chain variable region comprises the following three complementary determining regions CDR: CDR1 as shown in SEQ ID No.8, CDR2 with the sequence of WAS, and CDR3 as shown in SEQ ID No.9. The light chain variable region has the advantages that the light chain variable region can be used for preparing the light chain variable region; the invention provides a specific monoclonal antibody of a foot and mouth disease virus non-structural protein 3D protein. A Western blotting test shows that the specific monoclonal antibody specifically reacts with the non-structural protein 3D; indirect immunofluorescence tests show that the antibody has good reactivity with an FMDV O-type strain.

The application discloses a monoclonal antibody and application. A monoclonal antibody is secreted by a hybridoma cell strain 6B12G10, and an antigen epitope recognized by the monoclonal antibody is aa130-aa134 of a P30 protein of a gene I type African swine fever virus. An amino acid aa131 of the P30 protein is E. The application prepares a monoclonal antibody capable of identifying the P30 antigen of the gene I type African swine fever virus; the monoclonal antibody can directly distinguish the gene I type and the gene II type, the gene I / II recombinant type ASFV by using an indirect immunofluorescence technology; for type identification after infection of an ASFV weak strain, the application establishes a blocking ELISA method, and for the first time, effectively distinguishes whether the gene I type ASFV is infected or the gene II type, the gene I / II recombinant type ASFV is infected, effectively fills a differential diagnosis blank in the domestic and foreign aspects, and has important significance for tracing a gene I type ASFV infection.

This invention relates to the field of molecular biology, specifically to a nested PCR primer set, kit, and application for detecting porcine infectious pleuropneumonia. The kit, developed by establishing a nested PCR amplification primer set, can be used for the in vitro diagnosis of porcine infectious pleuropneumonia. It exhibits high sensitivity, detecting up to 0.355 pg / µL, which is nearly 100 times higher than that of conventional PCR (35.5 pg / µL). It also demonstrates strong specificity, overcoming the problems of low sensitivity and poor specificity associated with conventional PCR. Compared to existing indirect immunofluorescence and serological detection methods, it offers lower cost and a shorter detection cycle.

The invention discloses an application of licochalcone B (Lcochalcone B, LCB) in a medicine for preventing and treating porcine epidemic diarrhea, and belongs to the technical field of medicines. The antiviral effect of the licochalcone B on the porcine epidemic diarrhea virus (PEDV) at the level of Vero cells (African green monkey kidney cells) is researched through methods such as an indirect immunofluorescence experiment (IFA) and real-time fluorescent quantitative PCR (qRT-PCR), and experimental results show that the licochalcone B can remarkably inhibit proliferation of the porcine epidemic diarrhea virus. It is proved that licochalcone B has remarkable porcine epidemic diarrhea virus resisting activity, a brand-new effective candidate medicine is provided for prevention and treatment of porcine epidemic diarrhea, and the licochalcone B has good application prospects in the field of medicine for preventing and treating porcine epidemic diarrhea.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus (CSFV) recombinant E2 protein and application, and relates to the technical field of biology.The TK / gE double gene deletion PRV attenuated strain is used as a virus carrier, an exogenous CSFV E2 gene with a transmembrane region removed is inserted after a PRV gC signal peptide sequence, and a recombinant virus rPRV-delTK / gE-gC-E2 for expressing the gC N terminal and fusing with the PRV gC is constructed; Western blotting analysis and indirect immunofluorescence detection prove that the gC-E2 protein is successfully expressed.The recombinant virus immunized mice can produce specific antibodies against E2; after immunizing piglets, the piglets can produce an antibody level equivalent to that of a classical CSFV attenuated vaccine strain C strain.The rPRV-delTK / gE-gC-E2 obtained in the research is a promising bivalent live vaccine candidate strain.

This invention utilizes a machine learning model to analyze the crystal structure of the PEDV Nsp5 protein. Through virtual peptide screening, a peptide sequence KYRRQH (177080) with potential affinity for the target protein was identified. The 177080 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV Nsp5 protein. The affinity constant between the peptide and the target protein was determined using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 177080 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was assessed using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that 177080 significantly inhibited PEDV infection.

The application is based on machine learning model, and the polypeptide RFFMWH (170849) with potential is screened through polypeptide virtual screening technology based on the analysis of PEDV Nsp5 protein crystal structure. The sequence of 170849 is artificially synthesized, and the polypeptide is screened by using artificially expressed PEDV Nsp5 protein through ELISA experiment. The affinity constant of the polypeptide and the target protein is identified by surface plasmon resonance experiment (SPR). The cytotoxicity of the polypeptide 170849 is tested by CCK-8 kit. The virus infection inhibiting activity of the polypeptide is tested by fluorescence quantitative PCR and indirect immunofluorescence experiment. The results show that the sequence 170849 can significantly inhibit the infection of PEDV.

The invention relates to the technical field of biology, and particularly discloses a pea active peptide and application thereof in inhibiting porcine coronavirus. The toxicity of pea active peptides EHYDSEAILFKK with different concentrations on Vero cells and ST cells is determined through a CCK-8 test, and it is proved that the pea peptide has no toxic effect on the cells; indirect immunofluorescence, virus copy number, immunoblotting and half tissue infection amount are used for determining that the pea active peptide EHYDSEAILFKK has an inhibition effect on porcine epidemic diarrhea virus in Vero cells and porcine transmissible gastroenteritis virus in ST cells; animal experiments show that piglets with 200 [mu] M of pea active peptide can significantly inhibit in-vivo replication of PEDV and TGEV. Therefore, the pea active peptide can obviously inhibit the replication of the porcine epidemic diarrhea virus and the porcine transmissible gastroenteritis virus in vivo and in vitro, and has a broad-spectrum effect of resisting the porcine coronavirus.

The application discloses a kind of targeting cat calicivirus VP1-CDE protein chicken source single-chain antibody and its preparation and application, belong to biotechnology field.The single-chain antibody is selected from X2B2, X2E1 Or X2G5, its heavy chain variable region and light chain variable region amino acid sequence are respectively as shown in SEQ ID NO:1-6.The application is prokaryotic expression and purified VP1-CDE protein as antigen immunization chicken, amplifies VH And VL Gene and is spliced into scFv gene by (Gly4Ser) 3 linker, constructs library capacity not less than 5.25×10 7 CFU / mL phage display library, specific single-chain antibody clone is obtained by solid-phase panning, and its binding activity is verified by Western blot, ELISA, indirect immunofluorescence test after eukaryotic expression and purification.The results show that the three single-chain antibodies can specifically bind VP1-CDE protein and FCV virus particles, and there is no cross reaction, which provides key experimental materials for basic research of cat calicivirus, can be used for developing FCV rapid diagnostic reagent or kit, also provides candidate molecules for the development of FCV infection treatment drugs, and has important theoretical significance and application value.

The invention discloses a monoclonal antibody 3B3 capable of being specifically combined with a group A porcine rotavirus and application, the monoclonal antibody 3B3 is a murine monoclonal antibody, the heavy chain type of the monoclonal antibody 3B3 is IgG1, and the light chain type of the monoclonal antibody 3B3 is kappa; the monoclonal antibody 3B3 for resisting the group A porcine rotavirus is obtained by taking recombinant VP6 protein expressed by a CHO system as an immunogen to immunize a Balb / c mouse and screening through a hybridoma technology, has very excellent biological performance, not only has high affinity to rotavirus VP6 protein, but also has good reactivity to the group A porcine rotavirus. The sensitivity of the kit can reach 1: 256, and the kit has no cross reaction with positive serum of antibodies of six common diseases in pig farms. The method is relatively good in repeatability, and the coincidence rate with an indirect immunofluorescence detection result reaches 95.65%.

The invention relates to the technical field of antibodies, in particular to an anti-Getavirus monoclonal antibody 1D8, a nucleic acid molecule and application of the anti-Getavirus monoclonal antibody 1D8. The monoclonal antibody 1D8 secreted by the hybridoma cell strain 1D8 provided by the invention can be subjected to specific immunoreaction with GETV and GEV-E2 proteins, has good immunogenicity, good specificity and high sensitivity, can be widely applied to an immunodetection technology, can be used as an antibody for Western Blot and indirect immunofluorescence tests, and is used for identifying GETV and E2 proteins and measuring the content of GETV viruses; meanwhile, the antibody is obtained by using a conventional gene engineering or protein engineering method, so that the long-term cryopreservation antibody gene loss of hybridoma cells is avoided, the optimization of the antibody on gene and protein levels is also facilitated, and the specificity and affinity of the antibody are further improved.

The invention provides a preparation method and application of low-pathogenicity avian influenza virus positive serum, and belongs to the technical field of veterinary biological products. The low-pathogenicity avian influenza virus positive serum with high HI titer and neutralizing titer can be obtained by adopting a method of respectively immunizing the live virus and the inactivated vaccine once. The preparation method disclosed by the invention is not limited to the low-pathogenicity avian influenza virus of a single subtype. The positive serum prepared by the method has the characteristics of good specificity, strong sensitivity and the like, and can be used for technical detection of indirect immunofluorescence, western blot, immunohistochemistry and the like; and the kit can also be used for exogenous virus detection of poultry virus live vaccines, separation and identification of clinical viruses, identification and inspection of live vector vaccines, clinical monitoring of avian influenza viruses, epidemiological investigation and immune effect evaluation of related vaccines.

The application belongs to the technical field of biology and relates to a broad-spectrum monoclonal antibody for recognizing a linear antigen epitope at the C-terminal of foot-and-mouth disease virus VP2 protein and application thereof. The monoclonal antibody pOTB-1 is successfully constructed, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 6, and the amino acid sequence of the light chain variable region is as shown in SEQ ID No. 7. The biological activity of the antibody is verified by indirect immunofluorescence test, enzyme-linked immunosorbent assay and Western-blot. The antibody exhibits broad-spectrum reactivity to O type and A type FMDV and has strong binding affinity. The antibody recognizes a continuous linear B cell epitope at the C-terminal of the structural protein VP2. The epitope sequence is highly conserved among FMDV O type, A type and Asia1 type, which indicates that there is an inter-type common antigen site in the capsid protein VP2. A competitive ELISA detection method is established based on biotinylated pOTB-1, which provides a tool for the prevention and control of FMDV and serological detection, and lays a foundation for the design of FMDV marker vaccine and the evaluation of immunization effect.

The application is based on immune repertoire sequencing to screen fever with thrombocytopenia syndrome virus glycoprotein Gn monoclonal antibody and identify its biological characteristics. With purified SFTSV-Gn as a decoy, virus-specific B cells are fished from the B cell library of immunized female BALB / c mice, and 10x immune repertoire sequencing method is used in combination with bioinformatics analysis to select antibody sequences with potential binding activity, which are constructed into eukaryotic expression vector pcDNA3.4 for monoclonal antibody expression and purification, and biological activity is identified. From the 3544 captured B cells, 14 antibodies are selected, and functional verification shows that 12 antibodies can bind SFTSV-Gn glycoprotein, of which Gn-5 and Gn-7 antibodies have higher binding capacity; Western blot, indirect immunofluorescence test and flow cytometry prove that the antibody can specifically recognize SFTSV, and the effective concentration is as low as 2 μg / mL, which lays a foundation for the development of SFTSV rapid diagnostic reagent.

The application discloses a chicken MTRF1L protein monoclonal antibody and application thereof, and belongs to the technical field of biotechnology.The MTRF1L recombinant protein is used for immunizing animals, a sensitized B cell with the ability of secreting specific antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a chicken MTRF1L protein monoclonal antibody is obtained through screening.The application screens a high-quality nucleotide coding sequence of the MTRF1L gene through bioinformatics analysis, and uses the nucleotide coding sequence as an antigen to immunize BABE mice, a sensitized B cell with the ability of secreting specific MTRF1L antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a positive hybridoma cell is obtained through screening, and the cell supernatant is used for Western Blot and indirect immunofluorescence detection, and it is found that the monoclonal antibody has good specificity and high sensitivity, which lays a foundation for detection of the MTRF1L protein and research on pathological mechanisms of virus infection diseases.

The application discloses a kind of monoclonal antibody or its antigen-binding fragment of anti Oya virus nucleocapsid protein and application thereof.The monoclonal antibody F3E10 provided in the application has the characteristics such as high purity, high specificity, high affinity and high sensitivity, can specifically recognize the NP protein of OYAV, can be used as the detection antibody of Western blot and indirect immunofluorescence, is used for the qualitative detection of OYAV-NP protein and OYAV, and can realize the visualization marking and tracing of OYAV under microscope in combination with the secondary antibody labeled with fluorescence, is expected to be widely used in the research, detection and prevention and control of OYAV, and has important popularization and application value in the field of novel bunyavirus research.

A peptide and its sequence that can inhibit PEDV based on virtual screening. This invention utilizes a machine learning model to analyze the S1-CTD region of the PEDV S protein crystal structure. Through virtual peptide screening technology, a peptide sequence with potential affinity for the target protein, WHFNRP (115042), was identified. The 115042 sequence was artificially synthesized in a solid phase, and the peptide was screened using ELISA with artificially expressed PEDV S1 protein. The affinity constant between the peptide and the target protein was identified using surface plasmon resonance (SPR) assays. The cytotoxicity of peptide 115042 was tested using a CCK-8 assay kit. Its inhibitory activity against viral infection was tested using quantitative real-time PCR and indirect immunofluorescence assays. The results showed that the 115042 sequence significantly inhibited PEDV infection.